BRPI0608061A2 - método para abaixar os nìveis no sangue circulante de um lipìdio selecionado do grupo que consiste em colesterol ldl, triglicerìdios, colesterol total, e as misturas destes e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons - Google Patents

método para abaixar os nìveis no sangue circulante de um lipìdio selecionado do grupo que consiste em colesterol ldl, triglicerìdios, colesterol total, e as misturas destes e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons

Info

Publication number
BRPI0608061A2
BRPI0608061A2 BRPI0608061-8A BRPI0608061A BRPI0608061A2 BR PI0608061 A2 BRPI0608061 A2 BR PI0608061A2 BR PI0608061 A BRPI0608061 A BR PI0608061A BR PI0608061 A2 BRPI0608061 A2 BR PI0608061A2
Authority
BR
Brazil
Prior art keywords
triglycerides
mixtures
group
cholesterol
electrons
Prior art date
Application number
BRPI0608061-8A
Other languages
English (en)
Inventor
Simon Michael West
Esra Ogru
Roksan Libinaki
Original Assignee
Vital Health Sciences Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005901013A external-priority patent/AU2005901013A0/en
Application filed by Vital Health Sciences Pty Ltd filed Critical Vital Health Sciences Pty Ltd
Publication of BRPI0608061A2 publication Critical patent/BRPI0608061A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MéTODO PARA ABAIXAR OS NìVEIS NO SANGUE CIRCULANTE DE UM LIPìDIO SELECIONADO DO GRUPO QUE CONSISTE EM COLESTEROL LDL, TRIGLICERìDIOS, COLESTEROL TOTAL, E AS MISTURAS DESTES E USO DE UMA QUANTIDADE EFICAZ DE UM OU MAIS DERIVADOS DE FOSFATO DE UM OU MAIS AGENTES DE TRANSFERêNCIA DE ELéTRONS. Trata-se de uma terapia para abaixar os níveis no sangue de um lipídio selecionado do grupo que compreende colesterol LDL, trigliceridios, colesterol total, e as misturas destes, sendo que a terapia compreende a etapa de administraçào de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons.
BRPI0608061-8A 2005-03-03 2006-03-03 método para abaixar os nìveis no sangue circulante de um lipìdio selecionado do grupo que consiste em colesterol ldl, triglicerìdios, colesterol total, e as misturas destes e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons BRPI0608061A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2005901013A AU2005901013A0 (en) 2005-03-03 Compounds having lipid lowering properties
PCT/AU2006/000281 WO2006092025A1 (en) 2005-03-03 2006-03-03 Compounds having lipid lowering properties

Publications (1)

Publication Number Publication Date
BRPI0608061A2 true BRPI0608061A2 (pt) 2009-11-03

Family

ID=36940793

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608061-8A BRPI0608061A2 (pt) 2005-03-03 2006-03-03 método para abaixar os nìveis no sangue circulante de um lipìdio selecionado do grupo que consiste em colesterol ldl, triglicerìdios, colesterol total, e as misturas destes e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons

Country Status (10)

Country Link
EP (1) EP1861091B1 (pt)
JP (1) JP2008531603A (pt)
KR (1) KR20070108383A (pt)
CN (1) CN101132789A (pt)
AU (1) AU2006220248B2 (pt)
BR (1) BRPI0608061A2 (pt)
CA (1) CA2599612A1 (pt)
MX (1) MX2007010493A (pt)
RU (1) RU2428973C2 (pt)
WO (1) WO2006092025A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2794734C (en) 2010-03-30 2017-12-12 Phosphagenics Limited Transdermal delivery patch
ES2455124T5 (es) 2010-05-05 2018-05-08 Zora Biosciences Oy Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca
CN103154742B (zh) 2010-06-20 2017-11-21 佐拉生物科学公司 用于鉴定高风险冠状动脉疾病患者的脂质组学标志
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
WO2022155656A1 (en) 2021-01-13 2022-07-21 Rodan & Fields, Llc Cosmetic compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60197621A (ja) * 1984-03-19 1985-10-07 Hohnen Oil Co Ltd コレステロ−ル低下剤
US4603142A (en) * 1984-06-01 1986-07-29 Wisconsin Alumni Research Foundation Cholesterol lowering method of use
JPS61176535A (ja) * 1985-01-31 1986-08-08 Morishita Jintan Kk 腸溶性製剤
JP2854631B2 (ja) * 1989-11-21 1999-02-03 千寿製薬株式会社 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤
FR2657526B1 (fr) * 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
TW252918B (pt) * 1993-03-31 1995-08-01 Senju Pharma Co
CA2129509A1 (en) * 1993-09-10 1995-03-11 Kazumi Ogata Pharmaceutical composition for renal disorder and a dialysis solution for extracorporeal hemodialysis
CA2145229A1 (en) * 1994-03-29 1995-09-30 Tetsuya Toge Suppressory compositions against hepatic metastases of tumors
JP3396953B2 (ja) * 1994-05-10 2003-04-14 千寿製薬株式会社 網膜疾患予防・治療剤
US6022867A (en) * 1996-11-27 2000-02-08 Showa Denko Kabushiki Kaisha Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals
JPH10155429A (ja) * 1996-11-27 1998-06-16 Showa Denko Kk 動物に対するビタミンｅ供給方法および動物用トコフェロールリン酸エステル又はその塩類組成物
WO1999039716A1 (en) * 1998-02-03 1999-08-12 Senju Pharmaceutical Co., Ltd. Preventives and remedies for neuron digeneration-associated diseaseas
ITMI981586A1 (it) * 1998-07-10 2000-01-10 Giorgio Panin Vitamina e e suoi esteri per l'uso nel trattamento topico di patologie delle mucose
JP2001169731A (ja) * 1999-12-17 2001-06-26 Showa Denko Kk 動物体の脂質代謝改善剤
WO2002040033A1 (en) * 2000-11-14 2002-05-23 Vital Health Sciences Pty Ltd Formulation containing phosphate derivatives of electron transfer agents
EP1429782A4 (en) * 2001-09-26 2005-02-02 Vital Health Sciences Pty Ltd MODULATION OF VITAMIN STORAGE
AU2003211131A1 (en) * 2002-02-14 2003-09-04 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
JP4690305B2 (ja) * 2003-01-17 2011-06-01 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 抗増殖性質を有する化合物
US20090005348A1 (en) * 2005-12-23 2009-01-01 Vital Health Sciences Pty Ltd Compounds Having Cytokine Modulating Properties

Also Published As

Publication number Publication date
MX2007010493A (es) 2007-11-08
CN101132789A (zh) 2008-02-27
EP1861091A1 (en) 2007-12-05
KR20070108383A (ko) 2007-11-09
EP1861091B1 (en) 2013-12-11
RU2007130990A (ru) 2009-04-10
EP1861091A4 (en) 2010-01-27
AU2006220248B2 (en) 2012-06-21
CA2599612A1 (en) 2006-09-08
JP2008531603A (ja) 2008-08-14
WO2006092025A1 (en) 2006-09-08
AU2006220248A1 (en) 2006-09-08
RU2428973C2 (ru) 2011-09-20

Similar Documents

Publication Publication Date Title
PA8481201A1 (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino
GT200500339A (es) Compuestos y derivados de dibencil amina
CR6310A (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas
ES2544967T3 (es) Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas
PA8537201A1 (es) Agonistas de ppar
PA8539101A1 (es) Compuestos de ppar
BRPI0610321B8 (pt) imidazoquinolinas como inibidores de lipídeo cinase, seu uso e seu processo de preparação, e preparação farmacêutica
BR0316521A (pt) Ativadores de ppar
CL2012001124A1 (es) Composición farmacéutica que comprende un extracto terapéutico concentrado, que comprende fosfolípidos en concentración de 60 a 99% y uso para tratar enfermedades cardiovasculares, reducir niveles de triglicérido, reducir colesterol ldl y aumentar colesterol hdl.
BRPI0508584A (pt) lipìdio estruturado contendo composições e métodos com caracterìsticas promotoras de saúde e nutrição
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
DOP2007000044A (es) Compuestos y derivados de dibencilamina
CR7999A (es) Metodos y composiciones farmaceuticas para la obtencion confiable de niveles aceptables de testosterona en suero
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BR112018067597A8 (pt) célula progenitora de fígado adulto, população celular, material biológico, composição, método para avaliar a eficácia, o metabolismo, a estabilidade e/ou a toxicidade de um ou mais compostos, uso da célula ou população celular e kit
BRPI0512624A (pt) compostos heteroarila e fenilsulfamoìla substituìdos
BR112015024621A8 (pt) usos de dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica compreendendo a referida dose unitária, kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano e dose unitária de unidades formadoras de colônia de c. novyi
BRPI0719093B8 (pt) sistema transdérmico terapêutico com micro reservatórios de pares de ions
CR9012A (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina
BRPI0513673A (pt) método para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, veìculo utilizado na administração enteral de compostos biologicamente ativos, composição farmacêutica e uso de uma quantidade eficaz de um ou mais derivados de fosfato
UY31325A1 (es) Composiciones y métodos para tratar enfermedades y trastornos inmunologicos e inflamatorios
BRPI0607999A2 (pt) método para o alìvio de sintomas, o tratamento ou a prevenção do cáncer, uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais hidróxi cromanos selecionados do grupo que consiste em 7:8-dimetil 6-hidróxi cromanos (delta), 8-metil 6-hidróxi cromanos (gama), e as misturas dos mesmos, conjuntamente com um veìculo ou um diluente apropriado, método para a indução da apoptose celular, método para aumentar a eficácia de um agente anticáncer, método para aumentar a eficácia do licopeno, formulação farmacêutica
BRPI0803703A2 (pt) composição pesticida
BR0212887A (pt) Método para aumentar nìveis de uma forma de armazenagem de uma vitamina e uso de uma quantidade eficaz de um derivado de fosfato de uma vitamina
UA101035C2 (ru) Смягчающая композиция на основе вазелина, глицерина и вазелинового масла

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2211 DE 21/05/2013.